

Title (en)

METHOD FOR TREATING TUMORS HAVING HIGH LDL REQUIREMENTS EMPLOYING MTP INHIBITORS

Title (de)

BEHANDLUNGSMETHODE GEGEN TUMOREN MIT HOHEN ANFORDERUNGEN AN LDL, MITTELS MTP-INHIBITOREN

Title (fr)

PROCEDE DE TRAITEMENT DE TUMEURS AYANT DES BESOINS ELEVES EN LIPOPROTEINE DE BASSE DENSITE (LDL) A L'AIDE D'INHIBITEURS DE LA PROTEINE MICROSOMALE DE TRANSFERT DES TRIGLYCERIDES (MTP)

Publication

**EP 0954313 A4 20030702 (EN)**

Application

**EP 97932594 A 19970714**

Priority

- US 9712158 W 19970714
- US 2286396 P 19960724

Abstract (en)

[origin: WO9803174A1] A method is provided for treating hematologic tumors and solid tumors, including certain types of leukemias and metastatic tumors, having high LDL requirements employing a delipidating agent such as an MTP inhibitor to substantially reduce LDL blood levels. In addition, a method is provided for treating tumors of the above types having high LDL requirements, especially hematologic tumors such as certain leukemias, employing a delipidating compound to substantially remove native LDL, and then administering a cytotoxic agent carried in reconstituted LDL.

IPC 1-7

**A61K 31/445; A61P 3/06; A61P 31/00**

IPC 8 full level

**A61K 45/00** (2006.01); **A61K 31/00** (2006.01); **A61K 31/4468** (2006.01); **A61K 31/453** (2006.01); **A61K 31/4535** (2006.01); **A61K 31/454** (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 35/04** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)

**A61K 31/00** (2013.01); **A61K 31/4468** (2013.01); **A61K 31/453** (2013.01); **A61K 31/4535** (2013.01); **A61K 31/454** (2013.01); **A61K 45/06** (2013.01); **A61P 3/06** (2017.12); **A61P 31/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 35/04** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

- [DY] EP 0584446 A2 19940302 - SQUIBB & SONS INC [US]
- [XY] MALTESE, W. A.; DEFENDINI, R.; GREEN, R. A.; SHERIDAN, K. M.; DONLEY, D. K.: "Suppression of Murine Neuroblastoma Growth In Vivo by Mevinolin, a Competitive Inhibitor of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase", JOURNAL OF CLINICAL INVESTIGATION, vol. 76, - 1 November 1985 (1985-11-01), pages 1748 - 1754, XP009010279
- [X] THIBAULT, A.; SAMID, D.; TOMPKINS, A C; FIGG, W J; COOPER, M R; HOHL R J; TREPEL, J; LIANG, B; PATRONAS, N; VENZON, D J; REED, E: "Phase I Study of Lovastatin, an Inhibitor of the Mevalonate Pathway, in Patients with Cancer", CLINICAL CANCER RESEARCH, vol. 2, pages 483 - 491, XP001147434
- [Y] MIKULSKI S M ET AL: "SYNERGISM BETWEEN A NOVEL AMPHIBIAN OOCYTE RIBONUCLEASE AND LOVASTATIN IN INDUCING CYTOSTATIC AND CYTOTOXIC EFFECTS IN HUMAN LUNG AND PANCREATIC CARCINOMA CELL LINES", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 66, no. 2, August 1992 (1992-08-01), pages 304 - 310, XP000857575, ISSN: 0007-0920
- See references of WO 9803174A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**WO 9803174 A1 19980129**; AU 3600897 A 19980210; AU 712303 B2 19991104; CA 2261162 A1 19980129; EP 0954313 A1 19991110; EP 0954313 A4 20030702; JP 2002513379 A 20020508

DOCDB simple family (application)

**US 9712158 W 19970714**; AU 3600897 A 19970714; CA 2261162 A 19970714; EP 97932594 A 19970714; JP 50701298 A 19970714